Literature DB >> 9682338

Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile.

K Hoppenbrouwers1, R Lagos, B Swennen, C Ethevenaux, J Knops, M M Levine, J Desmyter.   

Abstract

To document any unexpected differences in the immune response between study populations and to evaluate immunogenicity and safety of a simplified presentation (dual-chamber syringe) of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine, a multicentre, randomized, comparative study was conducted in Belgium and Chile. A total of 537 healthy infants, 270 in Chile and 267 in Belgium, received PRP-T and DTP vaccines combined in a dual-chamber syringe (D-Ch group, DTP/PRP-T, reconstituted by pressing the plunger of the syringe immediately before injection, n = 239) or combined in a single-chamber syringe (C-In group, DTP@PRP-T, reconstituted immediately before injection, n = 61) or in separate injections (S-In group, DTP + PRP-T, simultaneously injected at separate sites, n = 237) at 3, 4, and 5 months of age. Serum samples were collected before vaccination and at 6 months of age. In the D-Ch group, the incidence of adverse events was comparable to administration of DTP vaccine alone. Higher rates of local and systemic reactions were observed in the Chilean population, possibly due to differences in surveillance practice. The immune response to each vaccine component compared well to that of the separate administration of PRP-T and DTP vaccines, except for higher post-immunization anti-PRP geometric mean titre (GMT) values after separate injections (25.6 micrograms mL-1) than after combined injection with the dual-chamber syringe (17.6 micrograms mL-1) (p = 0.001). An unexpected 'syringe' effect was seen: a greater post-immunization anti-PRP GMT was observed in the D-Ch group (17.6 micrograms mL-1) than in the C-In group (7.7 micrograms mL-1) (p = 0.0001). Whereas pre-immunization GMTs of some antibodies were significantly lower in Chilean than in Belgian infants, the post-immunization GMTs of Chilean infants were two to three times greater for all of the antibodies studied (p < 0.005). Differences in reactogenicity and in the immune response between the study populations or the different vaccine presentations were striking, but are probably of no clinical relevance. The convenient dual-chamber syringe presentation of DTP and PRP-T vaccines is safe and highly immunogenic.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682338     DOI: 10.1016/s0264-410x(97)00303-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Naturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in Mali.

Authors:  Julia Hutter; Marcela F Pasetti; Doh Sanogo; Milagritos D Tapia; Samba O Sow; Myron M Levine
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

2.  Evaluation of the immunogenicity and safety of an indigenously developed DTwP-Hib tetravalent combination vaccine (Shan 4) with EasyFourTM in Indian infants administered per EPI schedule: a phase III trial.

Authors:  Mandeep S Dhingra; Raman Rao; Swarnarekha Bhat; Rajan Joshi; Veena Kalra; Harish R Parikh; S Narasimha Rao; G R Sethi; Nitin Shah; M Muzaffaruddin
Journal:  Hum Vaccin       Date:  2010-07

Review 3.  Acellular pertussis vaccine safety and efficacy in children, adolescents and adults.

Authors:  Janet R Casey; Michael E Pichichero
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom.

Authors:  Dominic F Kelly; E Richard Moxon; Ly-Mee Yu; Andrew J Pollard
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

5.  Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.

Authors:  Philippe A Denoël; David Goldblatt; Isabel de Vleeschauwer; Jeanne-Marie Jacquet; Michael E Pichichero; Jan T Poolman
Journal:  Clin Vaccine Immunol       Date:  2007-08-15

6.  Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh.

Authors:  Daniel T Leung; Taher Uddin; Peng Xu; Amena Aktar; Russell A Johnson; Mohammad Arif Rahman; Mohammad Murshid Alam; Meagan Kelly Bufano; Grace Eckhoff; Ying Wu-Freeman; Yanan Yu; Tania Sultana; Farhana Khanam; Amit Saha; Fahima Chowdhury; Ashraf I Khan; Richelle C Charles; Regina C Larocque; Jason B Harris; Stephen B Calderwood; Pavol Kovác; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2013-03-20

7.  Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.

Authors:  Alassane Dicko; Yahia Dicko; Amadou Barry; Youssoufa Sidibe; Almahamoudou Mahamar; Gaoussou Santara; Amagana Dolo; Aminata Diallo; Ogobara Doumbo; Fakrudeen Shafi; Nancy François; Juan Pablo Yarzabal; Ana Strezova; Dorota Borys; Lode Schuerman
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children.

Authors:  Alassane Dicko; Gaoussou Santara; Almahamoudou Mahamar; Youssoufa Sidibe; Amadou Barry; Yahia Dicko; Aminata Diallo; Amagana Dolo; Ogobara Doumbo; Fakrudeen Shafi; Nancy François; Ana Strezova; Dorota Borys; Lode Schuerman
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

Review 9.  Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults.

Authors:  Federico Martinón-Torres; Terry Nolan; Daniela Toneatto; Angelika Banzhoff
Journal:  Hum Vaccin Immunother       Date:  2019-07-09       Impact factor: 3.452

10.  Variation between Populations in the Innate Immune Response to Vaccine Adjuvants.

Authors:  Tobias R Kollmann
Journal:  Front Immunol       Date:  2013-04-02       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.